JP2018526033A5 - - Google Patents

Download PDF

Info

Publication number: JP2018526033A5
Authority: JP; Japan
Prior art keywords: receptor; cancer; cell; dysfunctional; chimeric antigen
Prior art date: 2016-09-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2018532485A

Other languages

English (en)

Japanese (ja)

Other versions

JP6957471B2 (ja

JP2018526033A (ja

Filing date

2016-09-10

Publication date

2020-09-10

2016-09-10 Application filed filed Critical

2016-09-10 Priority claimed from PCT/AU2016/050851 external-priority patent/WO2017041143A1/en

2018-09-13 Publication of JP2018526033A publication Critical patent/JP2018526033A/ja

2020-09-10 Publication of JP2018526033A5 publication Critical patent/JP2018526033A5/ja

2021-10-05 Priority to JP2021164222A priority Critical patent/JP7253020B2/ja

2021-11-02 Application granted granted Critical

2021-11-02 Publication of JP6957471B2 publication Critical patent/JP6957471B2/ja

Status Active legal-status Critical Current

2036-09-10 Anticipated expiration legal-status Critical

Links

210000004027 cell Anatomy 0.000 claims description 74
108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 55
102000005962 receptors Human genes 0.000 claims description 55
108020003175 receptors Proteins 0.000 claims description 55
238000000034 method Methods 0.000 claims description 30
239000000427 antigen Substances 0.000 claims description 22
108091007433 antigens Proteins 0.000 claims description 22
102000036639 antigens Human genes 0.000 claims description 22
108020004707 nucleic acids Proteins 0.000 claims description 20
102000039446 nucleic acids Human genes 0.000 claims description 20
150000007523 nucleic acids Chemical class 0.000 claims description 20
210000001744 T-lymphocyte Anatomy 0.000 claims description 15
206010028980 Neoplasm Diseases 0.000 claims description 14
201000011510 cancer Diseases 0.000 claims description 14
239000008194 pharmaceutical composition Substances 0.000 claims description 9
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 8
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 8
108091008034 costimulatory receptors Proteins 0.000 claims description 8
230000003213 activating effect Effects 0.000 claims description 5
150000001413 amino acids Chemical group 0.000 claims description 5
206010006187 Breast cancer Diseases 0.000 claims description 4
208000026310 Breast neoplasm Diseases 0.000 claims description 4
108010087819 Fc receptors Proteins 0.000 claims description 4
102000009109 Fc receptors Human genes 0.000 claims description 4
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
230000019491 signal transduction Effects 0.000 claims description 4
206010005003 Bladder cancer Diseases 0.000 claims description 3
102100027207 CD27 antigen Human genes 0.000 claims description 3
101150013553 CD40 gene Proteins 0.000 claims description 3
206010008342 Cervix carcinoma Diseases 0.000 claims description 3
206010009944 Colon cancer Diseases 0.000 claims description 3
208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 3
101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 3
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 3
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 3
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
206010060862 Prostate cancer Diseases 0.000 claims description 3
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
208000000453 Skin Neoplasms Diseases 0.000 claims description 3
208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 3
208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
206010057644 Testis cancer Diseases 0.000 claims description 3
101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 3
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 3
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
201000010881 cervical cancer Diseases 0.000 claims description 3
208000029742 colonic neoplasm Diseases 0.000 claims description 3
210000002919 epithelial cell Anatomy 0.000 claims description 3
201000004101 esophageal cancer Diseases 0.000 claims description 3
206010017758 gastric cancer Diseases 0.000 claims description 3
201000005202 lung cancer Diseases 0.000 claims description 3
208000020816 lung neoplasm Diseases 0.000 claims description 3
201000000849 skin cancer Diseases 0.000 claims description 3
201000011549 stomach cancer Diseases 0.000 claims description 3
201000003120 testicular cancer Diseases 0.000 claims description 3
201000005112 urinary bladder cancer Diseases 0.000 claims description 3
239000013603 viral vector Substances 0.000 claims description 3
208000003174 Brain Neoplasms Diseases 0.000 claims description 2
208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
206010025323 Lymphomas Diseases 0.000 claims description 2
208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
206010033128 Ovarian cancer Diseases 0.000 claims description 2
206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
206010038389 Renal cancer Diseases 0.000 claims description 2
208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
206010062129 Tongue neoplasm Diseases 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
201000010982 kidney cancer Diseases 0.000 claims description 2
208000032839 leukemia Diseases 0.000 claims description 2
210000000265 leukocyte Anatomy 0.000 claims description 2
208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
210000004698 lymphocyte Anatomy 0.000 claims description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
201000000050 myeloid neoplasm Diseases 0.000 claims description 2
210000000581 natural killer T-cell Anatomy 0.000 claims description 2
210000000822 natural killer cell Anatomy 0.000 claims description 2
239000002773 nucleotide Substances 0.000 claims description 2
125000003729 nucleotide group Chemical group 0.000 claims description 2
201000004228 ovarian endometrial cancer Diseases 0.000 claims description 2
201000002528 pancreatic cancer Diseases 0.000 claims description 2
208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
206010038038 rectal cancer Diseases 0.000 claims description 2
201000001275 rectum cancer Diseases 0.000 claims description 2
201000002510 thyroid cancer Diseases 0.000 claims description 2
201000006134 tongue cancer Diseases 0.000 claims description 2
230000004068 intracellular signaling Effects 0.000 claims 2
108010083359 Antigen Receptors Proteins 0.000 claims 1
102000006306 Antigen Receptors Human genes 0.000 claims 1
108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
241000700605 Viruses Species 0.000 claims 1
230000002463 transducing effect Effects 0.000 claims 1
102000004127 Cytokines Human genes 0.000 description 12
108090000695 Cytokines Proteins 0.000 description 12
125000003275 alpha amino acid group Chemical group 0.000 description 12
239000012634 fragment Substances 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
239000000523 sample Substances 0.000 description 9
239000013598 vector Substances 0.000 description 9
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 7
108091008146 restriction endonucleases Proteins 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
102000013691 Interleukin-17 Human genes 0.000 description 5
108050003558 Interleukin-17 Proteins 0.000 description 5
108010002350 Interleukin-2 Proteins 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
238000010586 diagram Methods 0.000 description 5
238000001962 electrophoresis Methods 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 4
108090000174 Interleukin-10 Proteins 0.000 description 4
230000011664 signaling Effects 0.000 description 4
108010065805 Interleukin-12 Proteins 0.000 description 3
108090000172 Interleukin-15 Proteins 0.000 description 3
108010002586 Interleukin-7 Proteins 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
238000010361 transduction Methods 0.000 description 3
230000026683 transduction Effects 0.000 description 3
108091023037 Aptamer Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
102100037850 Interferon gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
108090000176 Interleukin-13 Proteins 0.000 description 2
108090000171 Interleukin-18 Proteins 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
108090001007 Interleukin-8 Proteins 0.000 description 2
108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
238000003501 co-culture Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000009438 IgE Receptors Human genes 0.000 description 1
108010073816 IgE Receptors Proteins 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
206010046885 vaginal cancer Diseases 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1

JP2018532485A 2015-09-11 2016-09-10 キメラ抗原受容体およびその使用 Active JP6957471B2 (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP2021164222A JP7253020B2 (ja)	2015-09-11	2021-10-05	キメラ抗原受容体およびその使用

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AU2015903719A AU2015903719A0 (en)		2015-09-11	Chimeric antigen receptor and uses thereof
AU2015903719		2015-09-11
PCT/AU2016/050851 WO2017041143A1 (en)	2015-09-11	2016-09-10	Chimeric antigen receptors and uses thereof

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2021164222A Division JP7253020B2 (ja)	2015-09-11	2021-10-05	キメラ抗原受容体およびその使用

Publications (3)

Publication Number	Publication Date
JP2018526033A JP2018526033A (ja)	2018-09-13
JP2018526033A5 true JP2018526033A5 (2)	2020-09-10
JP6957471B2 JP6957471B2 (ja)	2021-11-02

Family

ID=58240468

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
JP2018532485A Active JP6957471B2 (ja)	2015-09-11	2016-09-10	キメラ抗原受容体およびその使用
JP2021164222A Active JP7253020B2 (ja)	2015-09-11	2021-10-05	キメラ抗原受容体およびその使用
JP2023047606A Active JP7822340B2 (ja)	2015-09-11	2023-03-24	キメラ抗原受容体およびその使用
JP2025052912A Pending JP2025098188A (ja)	2015-09-11	2025-03-27	キメラ抗原受容体およびその使用

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
JP2021164222A Active JP7253020B2 (ja)	2015-09-11	2021-10-05	キメラ抗原受容体およびその使用
JP2023047606A Active JP7822340B2 (ja)	2015-09-11	2023-03-24	キメラ抗原受容体およびその使用
JP2025052912A Pending JP2025098188A (ja)	2015-09-11	2025-03-27	キメラ抗原受容体およびその使用

Country Status (8)

Country	Link
US (3)	US12121539B2 (2)
EP (2)	EP3816294A1 (2)
JP (4)	JP6957471B2 (2)
KR (2)	KR20250058773A (2)
CN (2)	CN114891116A (2)
AU (4)	AU2016318230B2 (2)
ES (1)	ES2848478T3 (2)
WO (1)	WO2017041143A1 (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI3226897T1 (sl)	2014-12-05	2021-08-31	Memorial Sloan Kettering Cancer Center	Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
US12121539B2 (en) *	2015-09-11	2024-10-22	Biosceptre (Aust) Pty Ltd	Chimeric antigen receptors and uses thereof
PL233352B1 (pl) *	2016-09-15	2019-10-31	Adamed Spolka Z Ograniczona Odpowiedzialnoscia	Przeciwnowotworowe białko fuzyjne
PT3703750T (pt)	2017-11-01	2025-01-17	Memorial Sloan Kettering Cancer Center	Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
MX2020004568A (es)	2017-11-06	2020-10-05	Juno Therapeutics Inc	Combinación de una terapia celular y un inhibidor de gamma secretasa.
CN119193493A (zh)	2017-12-08	2024-12-27	朱诺治疗学股份有限公司	生产工程化t细胞组合物的过程
EP3735265A4 (en)	2018-01-03	2021-11-10	Qu Biologics Inc.	INNATE TARGETING OF ADOPTIVE CELL THERAPIES
JP2021514648A (ja) *	2018-03-01	2021-06-17	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	新規の標的抗原結合部分のための特異性アッセイ
CN112955184A (zh) *	2018-03-15	2021-06-11	基本解决方案公司	可编程免疫细胞受体复合物系统
CN112166193A (zh) *	2018-05-21	2021-01-01	生物权威（英国）有限公司	具有经修饰的接头结构域的嵌合抗原受体及其用途
CN110856724B (zh) *	2018-08-24	2022-05-27	杭州康万达医药科技有限公司	包含核酸及car修饰的免疫细胞的治疗剂及其应用
MA54078A (fr)	2018-11-01	2021-09-15	Juno Therapeutics Inc	Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
CN114173811A (zh) *	2019-07-26	2022-03-11	生物权威(澳大利亚)有限责任公司	P2x7受体靶向治疗
EP4304610A4 (en) *	2021-03-11	2025-03-05	Biosceptre (Aust) Pty Ltd	Novel cell therapy system
US20240368282A1 (en) *	2021-09-01	2024-11-07	Biosceptre (Aust) Pty Ltd	Methods and compositions for stimulating immune activity
CN120187461A (zh) *	2022-09-14	2025-06-20	生物权威(澳大利亚)有限责任公司	免疫细胞的体内检测
CN120166997A (zh) *	2022-09-14	2025-06-17	生物权威(澳大利亚)有限责任公司	检测免疫细胞的方法
JP2025531675A (ja) *	2022-09-14	2025-09-25	バイオセプター（オースト）プロプライエタリー・リミテッド	操作された免疫細胞の富化
WO2025054416A1 (en) *	2023-09-06	2025-03-13	The Regents Of The University Of California	Methods for treating cancer

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4579821A (en)	1981-11-23	1986-04-01	University Patents, Inc.	Control of DNA sequence transcription
US4601978A (en)	1982-11-24	1986-07-22	The Regents Of The University Of California	Mammalian metallothionein promoter system
US4940661A (en)	1984-05-17	1990-07-10	Genentech, Inc.	Metallothionein transcription control sequences and use thereof
US5512483A (en)	1993-05-21	1996-04-30	Mcgill University	Expression vectors responsive to steroid hormones
US5464758A (en)	1993-06-14	1995-11-07	Gossen; Manfred	Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
PL323587A1 (en)	1995-05-26	1998-04-14	Zeneca Ltd	Gene changing-over system including edisone receptor
US5851796A (en)	1995-06-07	1998-12-22	Yale University	Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes
AUPP991199A0 (en)	1999-04-21	1999-05-13	University Of Sydney, The	Methods for diagnosing pre-cancerous and cancerous conditions
AU4533300A (en)	1999-09-16	2001-04-17	Liangqi Zhang	A pressure-reducing diaphragm of carburettor
AUPQ968700A0 (en)	2000-08-28	2000-09-21	Intreat Pty Limited	Treatment of urinary incontinence
AUPR201500A0 (en)	2000-12-11	2001-01-11	Biosceptre Pty Ltd	Methods for identifying pre-neoplastic and neoplastic states in mammals
JP4384852B2 (ja)	2001-01-17	2009-12-16	イントリートピーティーワイリミテッド	非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
US20030203411A1 (en) *	2001-06-05	2003-10-30	Sabbadini Roger A.	Methods of minicell-based delivery
CN100497386C (zh)	2001-09-03	2009-06-10	因特里特有限公司	非功能性p2x7受体的抗体及其应用
CA2402930A1 (en) *	2002-09-19	2004-03-19	William Herman	Targeted ligands
JP2008511286A (ja)	2004-06-02	2008-04-17	ダイアテック・ピーティワイ・リミテッド	サメ類のＩｇＮＡＲドメインに基づく結合成分
WO2008043146A1 (en)	2006-10-10	2008-04-17	Biosceptre International Limited	Antibodies against non functional p2x7 receptor
JP2010505426A (ja)	2006-10-10	2010-02-25	バイオスセプターインターナショナルリミテッド	非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
JP2010536341A (ja) *	2007-08-15	2010-12-02	アムニクス，インコーポレイテッド	生物学的に活性なポリペプチドの特性を改変するための組成物および方法
ES2619681T3 (es)	2007-09-14	2017-06-26	Biosceptre (Aust) Pty Ltd	Novedosos epítopos P2X7
ATE542139T1 (de)	2007-09-14	2012-02-15	Biosceptre Int Ltd	Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
US8840186B2 (en)	2007-11-07	2014-09-23	L&P Swiss Holding Ag	Support assembly and corresponding seat structure
CN102143978B (zh)	2008-07-04	2015-02-18	生物权威国际有限公司	抗p2x7肽和表位
JP5164806B2 (ja)	2008-11-12	2013-03-21	サンデン株式会社	車両用通信制御装置
CN102858985A (zh) *	2009-07-24	2013-01-02	西格马-奥尔德里奇有限责任公司	基因组编辑方法
EP2467404B1 (en)	2009-08-20	2015-09-30	Biosceptre International Limited	Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en)	2009-12-24	2011-06-30	Biosceptre International Limited	Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en)	2010-09-10	2017-11-08	Biosceptre (Aust) Pty Ltd	Companion animal cancer treatments with an anti p2x7 antibody
EP2646461A2 (en)	2010-12-03	2013-10-09	Cyclogenix Ltd	VARIANTS OF igNAR
PH12013501201A1 (en) *	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
US9233125B2 (en) *	2010-12-14	2016-01-12	University Of Maryland, Baltimore	Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
MX349321B (es)	2011-07-01	2017-07-21	Biosceptre (Aust) Pty Ltd	Terapia combinada.
WO2014055657A1 (en)	2012-10-05	2014-04-10	The Trustees Of The University Of Pennsylvania	Use of a trans-signaling approach in chimeric antigen receptors
WO2015121454A1 (en) *	2014-02-14	2015-08-20	Cellectis	Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
KR102558502B1 (ko)	2014-12-05	2023-07-20	시티 오브 호프	Ｃｓ1 표적화된 키메라 항원 수용체-변형된 ｔ 세포
WO2016123143A1 (en)	2015-01-26	2016-08-04	The University Of Chicago	CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
US20180037650A1 (en)	2015-04-02	2018-02-08	Biosceptre (Uk) Limited	Pain Treatment
US12121539B2 (en)	2015-09-11	2024-10-22	Biosceptre (Aust) Pty Ltd	Chimeric antigen receptors and uses thereof
WO2017181001A1 (en)	2016-04-15	2017-10-19	Trustees Of Dartmouth College	High affinity b7-h6 antibodies and antibody fragments
WO2018017649A1 (en)	2016-07-19	2018-01-25	Unum Therapeutics Inc.	Use of antibody-coupled t cell receptor (actr) with multiple anti-cancer antibodies in cancer treatment
US20190263928A1 (en)	2016-09-30	2019-08-29	Baylor College Of Medicine	Adaptive chimeric antigen receptor t-cell design
MX2019004410A (es)	2016-10-21	2019-09-26	Biosceptre Uk Ltd	Particulas citotoxicas.
CN112166193A (zh)	2018-05-21	2021-01-01	生物权威（英国）有限公司	具有经修饰的接头结构域的嵌合抗原受体及其用途
CN114173811A (zh)	2019-07-26	2022-03-11	生物权威(澳大利亚)有限责任公司	P2x7受体靶向治疗

2016
- 2016-09-10 US US15/759,046 patent/US12121539B2/en active Active
- 2016-09-10 EP EP20197564.6A patent/EP3816294A1/en active Pending
- 2016-09-10 ES ES16843305T patent/ES2848478T3/es active Active
- 2016-09-10 CN CN202210429775.5A patent/CN114891116A/zh active Pending
- 2016-09-10 CN CN201680064592.0A patent/CN108350462B/zh active Active
- 2016-09-10 KR KR1020257012877A patent/KR20250058773A/ko active Pending
- 2016-09-10 AU AU2016318230A patent/AU2016318230B2/en active Active
- 2016-09-10 JP JP2018532485A patent/JP6957471B2/ja active Active
- 2016-09-10 KR KR1020187010203A patent/KR20180043841A/ko not_active Ceased
- 2016-09-10 EP EP16843305.0A patent/EP3347474B1/en active Active
- 2016-09-10 WO PCT/AU2016/050851 patent/WO2017041143A1/en not_active Ceased
2020
- 2020-07-28 AU AU2020210185A patent/AU2020210185C1/en active Active
- 2020-10-23 US US17/078,969 patent/US20210038649A1/en not_active Abandoned
2021
- 2021-10-05 JP JP2021164222A patent/JP7253020B2/ja active Active
2022
- 2022-02-24 AU AU2022201263A patent/AU2022201263B2/en active Active
2023
- 2023-03-24 JP JP2023047606A patent/JP7822340B2/ja active Active
2024
- 2024-07-24 US US18/783,109 patent/US20250101080A1/en active Pending
- 2024-08-07 AU AU2024205598A patent/AU2024205598B2/en active Active
2025
- 2025-03-27 JP JP2025052912A patent/JP2025098188A/ja active Pending

Publication	Publication Date	Title
JP2018526033A5 (2)	2020-09-10
JP7737440B2 (ja)	2025-09-10	抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法
CN108884164B (zh)	2022-12-27	用于免疫疗法的经修饰细胞
EP3472205B1 (en)	2020-12-16	Chimeric antigen receptor
CN109069537B (zh)	2022-04-15	共刺激结构域中具有重复结合基序的car
CN112368298A (zh)	2021-02-12	嵌合跨膜蛋白及其用途
JP2018529327A5 (2)	2019-10-03
CN113646335A (zh)	2021-11-12	使用对b细胞成熟抗原具有特异性的嵌合抗原受体的治疗的方法
CN114391021B (zh)	2026-01-16	TGF-β受体和使用方法
CN115916833B (zh)	2023-10-03	靶向b7h3的抗原结合多肽及其应用
WO2022247795A1 (zh)	2022-12-01	靶向Claudin18.2的纳米抗体及其用途
US12331315B2 (en)	2025-06-17	Chimeric antigen receptor
CN110678480A (zh)	2020-01-10	嵌合多肽和改变它们的在细胞膜中的定位的方法
JP2025536940A (ja)	2025-11-12	新規ｃｄ１９バインダー、それを含むｃａｒ－ｔ構造体、およびその使用方法
TWI849430B (zh)	2024-07-21	Ｇｐｃ３結合分子
KR20230124656A (ko)	2023-08-25	전립선암 키메라 항원 수용체
US20250297282A1 (en)	2025-09-25	Viral-binding protein and related reagents, articles, and methods of use
CN112279915A (zh)	2021-01-29	Icos抗体、基因、载体、宿主细胞和icos拮抗剂
HK40072388A (zh)	2022-11-25	TGF-β受体和使用方法
WO2024210072A1 (ja)	2024-10-10	キメラタンパク質、核酸、ベクター、ｔ細胞又はｎｋ細胞、医薬組成物、組み合わせ物、組み合わせ医薬、及び標的抗原結合タンパク質
JP2025539151A (ja)	2025-12-03	Ｌｉｌｒｂ４を特異的に結合する合成ｔ細胞受容体抗原受容体およびその使用
HK40121523A (zh)	2025-09-12	多特异性蛋白及相关方法
CN117586411A (zh)	2024-02-23	一种结合tnfr2和ccr8的双特异性抗体
CN120225549A (zh)	2025-06-27	对b细胞成熟抗原(bcma)和/或跨膜激活剂和caml相互作用因子(taci)具有特异性的嵌合抗原受体
HK40013683A (en)	2020-08-07	Chimeric polypeptides and methods of altering their localisation in the cell membrane